For citations:
Motzer R., Porta C., Alekseev B., Rha S.Y., Choueiri T.K., Mendez-Vidal M.J., Hong S.H., Kapoor A., Goh J.C., Eto M., Bennett L., Wang J., Pan J.J., Saretsky T.L., Perini R.F., He C.S., Mody K., Cella D. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Cancer Urology. 2022;18(2):39-57. (In Russ.) https://doi.org/10.17650/1726-9776-2022-18-2-39-57
Email this article 